BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao X, Zhang S, Chen Y, Wen X, Chen M, Wang S, Zhang Y. Development of a novel six-long noncoding RNA signature predicting survival of patients with bladder urothelial carcinoma. J Cell Biochem 2019;120:19796-809. [PMID: 31338862 DOI: 10.1002/jcb.29285] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Wang Y, Lai S, Zhao L, Liu W, Liu S, Chen H, Wang J, Du G, Tang B. LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2. Cell Death Discov 2022;8:449. [DOI: 10.1038/s41420-022-01234-8] [Reference Citation Analysis]
2 Peña-flores JA, Bermúdez M, Ramos-payán R, Villegas-mercado CE, Soto-barreras U, Muela-campos D, Álvarez-ramírez A, Pérez-aguirre B, Larrinua-pacheco AD, López-camarillo C, López-gutiérrez JA, Garnica-palazuelos J, Estrada-macías ME, Cota-quintero JL, Barraza-gómez AA. Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma. Front Oncol 2022;12:965628. [DOI: 10.3389/fonc.2022.965628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gao X, Cai J. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer. Front Genet 2022;13:865204. [DOI: 10.3389/fgene.2022.865204] [Reference Citation Analysis]
4 Bieńkiewicz J, Romanowicz H, Szymańska B, Domańska-Senderowska D, Wilczyński M, Stepowicz A, Malinowski A, Smolarz B. Analysis of lncRNA sequences: FAM3D-AS1, LINC01230, LINC01315 and LINC01468 in endometrial cancer. BMC Cancer 2022;22:343. [PMID: 35351056 DOI: 10.1186/s12885-022-09426-2] [Reference Citation Analysis]
5 Lu H, Wu J, Liang L, Wang X, Cai H. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. Front Immunol 2022;13:803355. [PMID: 35154117 DOI: 10.3389/fimmu.2022.803355] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
6 Xu Z, Chen H, Sun J, Mao W, Chen S, Chen M. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence. Bioengineered 2021;12:11108-25. [PMID: 34738881 DOI: 10.1080/21655979.2021.2000122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Li W, Guo L, Tang W, Ma Y, Wang X, Shao Y, Zhao H, Ying J. Identification of DNA methylation biomarkers for risk of liver metastasis in early-stage colorectal cancer. Clin Epigenetics 2021;13:126. [PMID: 34108011 DOI: 10.1186/s13148-021-01108-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Yin T, Zhao D, Yao S. Identification of a Genome Instability-Associated LncRNA Signature for Prognosis Prediction in Colon Cancer. Front Genet 2021;12:679150. [PMID: 34163531 DOI: 10.3389/fgene.2021.679150] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Chen P, Guo H, Liu Y, Chen B, Zhao S, Wu S, Li W, Wang L, Jia K, Wang H, Jiang M, Tang X, Qi H, Dai C, Ye J, He Y. Aberrant methylation modifications reflect specific drug responses in small cell lung cancer. Genomics 2021;113:1114-26. [PMID: 33705885 DOI: 10.1016/j.ygeno.2020.12.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wu Y, Zhang L, He S, Guan B, He A, Yang K, Gong Y, Li X, Zhou L. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer. Aging (Albany NY) 2020;12:23306-25. [PMID: 33221763 DOI: 10.18632/aging.104115] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 10.7] [Reference Citation Analysis]
11 Glaß M, Dorn A, Hüttelmaier S, Haemmerle M, Gutschner T. Comprehensive Analysis of LincRNAs in Classical and Basal-Like Subtypes of Pancreatic Cancer. Cancers (Basel) 2020;12:E2077. [PMID: 32727085 DOI: 10.3390/cancers12082077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Song Y, Jin D, Chen J, Luo Z, Chen G, Yang Y, Liu X. Identification of an immune-related long non-coding RNA signature and nomogram as prognostic target for muscle-invasive bladder cancer. Aging (Albany NY) 2020;12:12051-73. [PMID: 32579540 DOI: 10.18632/aging.103369] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
13 Ban Y, Tan P, Cai J, Li J, Hu M, Zhou Y, Mei Y, Tan Y, Li X, Zeng Z, Xiong W, Li G, Li X, Yi M, Xiang B. LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Mol Oncol 2020;14:1282-96. [PMID: 32216017 DOI: 10.1002/1878-0261.12676] [Cited by in Crossref: 71] [Cited by in F6Publishing: 82] [Article Influence: 23.7] [Reference Citation Analysis]
14 Qiu H, Hu X, He C, Yu B, Li Y, Li J. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes. Front Genet 2020;11:12. [PMID: 32117435 DOI: 10.3389/fgene.2020.00012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]